{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:27Z","timestamp":1792601487193,"version":"4.5.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is associated with increased risk for osteoporotic fracture. We highlight RA-specific risk factors for bone mineral density (BMD) loss and fractures and considerations regarding the diagnosis and treatment of osteoporosis in patients with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Anticitrullinated protein antibody (ACPA) positivity, although associated with low BMD in early RA, is not associated with accelerated BMD loss over time when compared to ACPA negative individuals. Studies have found reduced BMD in individuals on low doses of glucocorticoids (GCs). Poor functional status and frailty are additional important risk factors for low BMD and fractures. Heightened fracture risk in RA may be mitigated by tight disease control, and biologic therapies are associated with more stable BMD compared to nonbiologic therapies. Evidence-based guidelines specific for treating osteoporosis in patients with RA do not exist. Thus, treatment decisions are based on general osteoporosis guidelines, taking into account additional RA-specific risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Recent studies have advanced knowledge of RA-specific risk factors for BMD loss and fractures. Future studies applying these findings to modify established fracture risk algorithms as well as evaluating osteoporosis treatments in RA cohorts are needed to reduce the risk of disabling fractures in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000789","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T15:05:46Z","timestamp":1614697546000},"page":"270-276","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":79,"title":["Osteoporosis and fractures in rheumatoid arthritis"],"prefix":"10.1097","volume":"33","author":[{"given":"Katherine D.","family":"Wysham","sequence":"first","affiliation":[{"name":"Rheumatology Section, VA Puget Sound Healthcare System, Division of Rheumatology, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua F.","family":"Baker","sequence":"additional","affiliation":[{"name":"Rheumatology and Epidemiology, Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M.","family":"Shoback","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, SFVAMC, UCSF, UCSF Training Program in Diabetes, Endocrinology and Metabolism, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-014-2968-y","article-title":"Rheumatoid arthritis patients with hip fracture: a nationwide study","volume":"26","author":"Lin","year":"2015","journal-title":"Osteoporos Int"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/rheumatology\/kep169","article-title":"Bone mineral density in the hand as a predictor for mortality in patients with rheumatoid arthritis","volume":"48","author":"Book","year":"2009","journal-title":"Rheumatology"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acr.22988","article-title":"Variations in radiographic procedure use for Medicare patients with rheumatoid arthritis","volume":"69","author":"Schmajuk","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/rheumatology\/keu162","article-title":"Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis","volume":"53","author":"Hauser","year":"2014","journal-title":"Rheumatology"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10067-019-04787-9","article-title":"Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis","volume":"39","author":"Tong","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-018-4218-8","article-title":"The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis","volume":"37","author":"Phuan-udom","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1515-1","article-title":"Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX\u00ae: a registry study of RA with osteoporosis\/fracture","volume":"20","author":"Cheng","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00774-015-0716-9","article-title":"Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment","volume":"35","author":"Mori","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10067-002-8274-7","article-title":"Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis","volume":"21","author":"Shibuya","year":"2002","journal-title":"Clin Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780300701","article-title":"Determinants of axial bone loss in rheumatoid arthritis","volume":"30","author":"Sambrook","year":"1987","journal-title":"Arthritis Rheum"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","article-title":"Generalised bone loss in patients with early rheumatoid arthritis","volume":"344","author":"Gough","year":"1994","journal-title":"Lancet"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/ard.2003.016253","article-title":"Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density","volume":"63","author":"Lodder","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/1529-0131(200106)44:6<1254::AID-ART216>3.0.CO;2-G","article-title":"Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease","volume":"44","author":"Kroot","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00296-020-04593-6","article-title":"Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database","volume":"40","author":"Lindner","year":"2020","journal-title":"Rheumatol Int"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00198-018-4473-1","article-title":"Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"29","author":"Jin","year":"2018","journal-title":"Osteoporos Int"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"e000671","DOI":"10.1136\/rmdopen-2018-000671","article-title":"Trends in hip fracture in patients with rheumatoid arthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999\u20132015). TREND-AR study","volume":"4","author":"Mazzucchelli","year":"2018","journal-title":"RMD Open"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI60975","article-title":"Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin","volume":"122","author":"Harre","year":"2012","journal-title":"J Clin Invest"},{"key":"R21-20250526","article-title":"The relation between autoantibodies and bone mineral density in patients with rheumatoid arthritis","author":"Amkreutz","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","article-title":"Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies","volume":"73","author":"Kleyer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00296-017-3674-9","article-title":"Anticitrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients","volume":"37","author":"Llorente","year":"2017","journal-title":"Rheumatol Int"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-016-1116-9","article-title":"Anticitrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis","volume":"18","author":"Bugatti","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/acr.23440","article-title":"Association of high anti-cyclic citrullinated peptide seropositivity and lean mass index with low bone mineral density in rheumatoid arthritis","volume":"70","author":"Wysham","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00223-017-0253-8","article-title":"Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients","volume":"101","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-019-1956-1","article-title":"Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis","volume":"21","author":"Tomizawa","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"e0202583","DOI":"10.1371\/journal.pone.0202583","article-title":"Association of high titers of anticarbamylated protein antibodies with decreased bone mineral density in early arthritis patients","volume":"13","author":"Regueiro","year":"2018","journal-title":"PLoS One"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1749-6632.1998.tb09563.x","article-title":"The role of IL-6 type cytokines and their receptors in bone","volume":"840","author":"Manolagas","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","article-title":"IL-1 mediates TNF-induced osteoclastogenesis","volume":"115","author":"Wei","year":"2005","journal-title":"J Clin Invest"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/03009740801998747","article-title":"Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis","volume":"37","author":"Book","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"R32-20250526","first-page":"1443","article-title":"Correlation between systemic osteoporosis and local bone erosion with rheumatoid arthritis patients in Chinese population","volume":"58","author":"Gong","year":"2019","journal-title":"Rheumatology"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.afos.2020.04.002","article-title":"Rheumatoid arthritis in tight disease control is no longer risk of bone mineral density loss","volume":"6","author":"Yoshii","year":"2020","journal-title":"Osteoporos Sarcopenia"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"M326","DOI":"10.1093\/gerona\/57.5.M326","article-title":"Relationship of interleukin-6 and tumor necrosis factor-\u03b1 with muscle mass and muscle strength in elderly men and women: the health ABC study","volume":"57","author":"Visser","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"526.e9","DOI":"10.1016\/j.amjmed.2005.10.049","article-title":"Inflammatory markers and loss of muscle mass (sarcopenia) and strength","volume":"119","author":"Schaap","year":"2006","journal-title":"Am J Med"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","article-title":"The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis","volume":"53","author":"Kume","year":"2014","journal-title":"Rheumatology"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","article-title":"Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-\u03b1 antibody: a prospective open-label pilot study","volume":"44","author":"Lange","year":"2005","journal-title":"Rheumatology"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N Engl J Med"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00198-005-1923-3","article-title":"High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass","volume":"17","author":"Natsui","year":"2006","journal-title":"Osteoporos Int"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12018-018-9242-3","article-title":"Glucocorticoid excess in bone and muscle","volume":"16","author":"Sato","year":"2018","journal-title":"Clin Rev Bone Miner Metab"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bone.2018.06.008","article-title":"The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials","volume":"114","author":"Blavnsfeldt","year":"2018","journal-title":"Bone"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-020-05360-w","article-title":"Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis","volume":"31","author":"Wang","year":"2020","journal-title":"Osteoporos Int"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/acr.23611","article-title":"Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis","volume":"71","author":"Wilson","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00296-016-3453-z","article-title":"Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study","volume":"36","author":"Kim","year":"2016","journal-title":"Rheumatol Int"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2019.06.006","article-title":"Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative","volume":"127","author":"Li","year":"2019","journal-title":"Bone"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"100284","DOI":"10.1016\/j.bonr.2020.100284","article-title":"Sex differences in frailty and its association with low bone mineral density in rheumatoid arthritis","volume":"12","author":"Wysham","year":"2020","journal-title":"Bone Rep"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3899\/jrheum.170513","article-title":"Muscle deficits in rheumatoid arthritis contribute to inferior cortical bone structure and trabecular bone mineral density","volume":"44","author":"Baker","year":"2017","journal-title":"J Rheumatol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2012.11.035","article-title":"Associations between body composition and bone density and structure in men and women across the adult age spectrum","volume":"53","author":"Baker","year":"2013","journal-title":"Bone"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11657-020-00719-2","article-title":"Association between grip strength and bone mineral density in general US population of NHANES","volume":"15","author":"Luo","year":"2020","journal-title":"Arch Osteoporos"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jbmr.2051","article-title":"Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)","volume":"29","author":"Compston","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"e921862","DOI":"10.12659\/MSM.921862","article-title":"Evaluation of risk factors for falls in patients with rheumatoid arthritis","volume":"26","author":"Mikos","year":"2020","journal-title":"Med Sci Monit"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","article-title":"Medications associated with fracture risk in patients with rheumatoid arthritis","volume":"78","author":"Ozen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.semarthrit.2019.08.003","article-title":"Effect of rheumatoid arthritis and age on metacarpal bone shaft geometry and density: a longitudinal pQCT study in postmenopausal women","volume":"50","author":"Aeberli","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u2014 2020 update executive summary","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2018.05.026","article-title":"In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?","volume":"113","author":"Martineau","year":"2018","journal-title":"Bone"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jbmr.3901","article-title":"HR-pQCT measures of bone microarchitecture predict fracture: systematic review and meta-analysis","volume":"35","author":"Mikolajewicz","year":"2020","journal-title":"J Bone Miner Res"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"104354","DOI":"10.1016\/j.phrs.2019.104354","article-title":"Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis","volume":"147","author":"Orsolini","year":"2019","journal-title":"Pharmacol Res"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/rheumatology\/kez655","article-title":"The impact of long-term biologics\/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis","volume":"59","author":"Chen","year":"2020","journal-title":"Rheumatology"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00198-020-05488-9","article-title":"Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study","volume":"31","author":"Shin","year":"2020","journal-title":"Osteoporos Int"},{"key":"R65-20250526","first-page":"CD001347","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","article-title":"Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/art.40156","article-title":"Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial","volume":"69","author":"Solomon","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:20:05Z","timestamp":1748280005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000789","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}